Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic umbilical cord blood-derived CXCR4-enriched T-regulatory cells CK0804

A preparation of allogeneic T-regulatory cells (Tregs) derived from umbilical cord blood (UCB) and enriched with C-X-C chemokine receptor type 4 (CXCR4), with potential immunomodulatory activity. Upon administration, allogeneic UCB-derived CXCR4-enriched Tregs CK0804 may promote immunologic homeostasis and modulate immune responses. CXCR4 enrichment promotes the traffic of the Tregs to the bone marrow and its retainment in the bone marrow, as bone marrow expresses the CXCR4 ligand stromal cell-derived factor 1 (CXCL12).

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	allogeneic UCB-derived CXCR4-enriched Tregs CK0804
Code name:	CK 0804 CK-0804 CK0804

allogeneic umbilical cord blood-derived CXCR4-enriched T-regulatory cells CK0804

Search NCI's Drug Dictionary